X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) have earned a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $9.3750.

Several analysts have weighed in on XFOR shares. Weiss Ratings raised X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 23rd. Wall Street Zen upgraded shares of X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Leerink Partners began coverage on shares of X4 Pharmaceuticals in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 target price on the stock. Finally, Guggenheim began coverage on shares of X4 Pharmaceuticals in a research report on Monday, March 9th. They set a “buy” rating and a $12.00 target price for the company.

X4 Pharmaceuticals Stock Up 5.2%

XFOR opened at $4.23 on Tuesday. The firm has a market capitalization of $398.97 million, a P/E ratio of -0.93 and a beta of 0.34. The company has a debt-to-equity ratio of 0.45, a current ratio of 10.18 and a quick ratio of 9.98. X4 Pharmaceuticals has a fifty-two week low of $1.35 and a fifty-two week high of $4.83. The company’s 50-day moving average is $4.08 and its 200 day moving average is $3.92.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. X4 Pharmaceuticals had a negative return on equity of 94.90% and a negative net margin of 1,106.30%.The company had revenue of $2.71 million during the quarter, compared to analyst estimates of $3.20 million. Research analysts expect that X4 Pharmaceuticals will post -0.77 earnings per share for the current fiscal year.

Institutional Investors Weigh In On X4 Pharmaceuticals

A number of hedge funds have recently made changes to their positions in XFOR. Bank of America Corp DE lifted its holdings in shares of X4 Pharmaceuticals by 20.3% in the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock worth $98,000 after acquiring an additional 22,485 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of X4 Pharmaceuticals by 5.4% in the 1st quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock worth $44,000 after acquiring an additional 9,690 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of X4 Pharmaceuticals by 112.5% in the 2nd quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock worth $185,000 after acquiring an additional 51,544 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of X4 Pharmaceuticals by 77.0% in the 3rd quarter. Vanguard Group Inc. now owns 410,485 shares of the company’s stock worth $1,404,000 after acquiring an additional 178,593 shares during the last quarter. Finally, Rosalind Advisors Inc. bought a new stake in shares of X4 Pharmaceuticals in the 3rd quarter worth approximately $5,283,000. 72.03% of the stock is currently owned by institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.